Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences
September 08 2022 - 8:00AM
Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or
(“the Company”), a global leader in the discovery and development
of innovative psychedelic-inspired therapeutics for improved mental
health outcomes, today announced it will participate in two
upcoming investor conferences in September 2022.
H.C. Wainwright
24th Annual Global Investment
ConferenceReunion’s management team will present at a
virtual fireside chat at the H.C. Wainwright 24th Annual Global
Investment Conference, taking place on September 12-14, 2022. A
recording of the fireside chat will be available on demand from
7:00 a.m. Eastern Time on Monday, September 12, 2022 for 90 days
through the following link:
https://journey.ct.events/view/715a2d59-3d1f-40a4-9314-0f1ac6b4902a.
Jefferies Innovation in Mental Health
SummitThe Reunion management team will participate in a
fireside chat at the Jefferies Innovation in Mental Health Summit,
taking place in New York City on September 22, 2022. The event will
be webcast and is accessible on Reunion’s investor relations
website for 90 days.
Institutional investors interested in scheduling
a meeting with Reunion’s management team, or for more information
on the conferences, please contact KCSA Strategic Communications at
Reunion@kcsa.com.
About Reunion Neuroscience Inc.,
(formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug
development, committed to innovating therapeutic solutions for
mental health conditions by developing proprietary serotonin
receptor agonist compounds. The Company’s lead asset, RE-104
(previously known as FT-104), is a proprietary, novel psychedelic
drug being developed for post-partum and treatment resistant
depression as a potential fast-acting antidepressant with durable
efficacy. Reunion is also developing the FT-200 series, which
includes compounds with potential for more selective serotonin
receptor activity with reduced psychoactivity for potential use in
more chronic treatment paradigms and indications.
Learn more at https://investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on Twitter and Instagram:
@reunionneuro.
To be added to the Reunion Neuroscience email
list, please email Reunion@kcsa.com with “REUN” in the subject
line.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding the Company and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of the Company and are based on assumptions and subject to risks
and uncertainties. Although management believes that the
assumptions underlying these statements are reasonable, they may
prove to be incorrect. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting the companies. Although the Company has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Additional information relating to
Field Trip, including its Annual Information Form, can be located
on the SEDAR website at www.sedar.com and on the EDGAR section of
the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
CONTACTS:
Reunion Neuroscience:Joseph del MoralChairman
& CEO(416) 219-1050joseph@reunionneuro.com
Media contacts:Caitlin KasunichKCSA Strategic
Communications(212) 896-1241reunion@kcsa.com
Investor contacts:Phil Carlson / Sophia
BashfordKCSA Strategic Communications(646) 573-0776 / (929)
246-7307reunion@kcsa.com
SOURCE Reunion Neuroscience Inc.
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Aug 2023 to Aug 2024